Importantly, roughly 90% of patients with pancreatic ductal adenocarcinomas have a KRAS mutation but, for those patients without a KRAS mutation, an NRG1 fusion can sometimes be found [26, 71, 72]. This evidence concerns the gene NRG1 and pancreatic ductal adenocarcinoma.